First Trust TCW Unconstrained Plus Bond ETF UCON 深 沪
等待开盘 10-30 09:30:00 美东时间
24.01
+0.040
+0.17%
华盛通- 最 高24.05
- 今 开23.99
- 成交量 87.20万股
- 最 低 23.94
- 昨 收 23.97
- 总市值 31.23亿
- 52周最高 24.73
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 23.435
- 委 比 0.00%
- 总股本 1.30亿
- 历史最高 24.73
- 量 比 1.29
- 振 幅 0.46%
- 历史最低 14.5248
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pharming Group announces third quarter 2026 revenues above market expectations
Pharming Group N.V. reported a 21% increase in Q3 2026 revenues to $117.6 million, driven by strong performance of RUCONEST® and Joenja®. Operating expenses remained stable at $74.6 million. The company tightened its 2026 revenue guidance to $380-$390 million and lowered operating expense guidance to $310-$315 million. Clinical updates include positive Phase II data for leniolisib and progress in the FALCON trial for Napazimone. Full Q3 results a...
10-22 05:00
Ducon Infratechnologies Announces Opening of Equity Rights Issue
Ducon Infratechnologies Ltd. ( ($IN:DUCON) ) has issued an update. Ducon Infrat...
08-31 15:43
Ahluwalia Contracts schedules board meet to review June-quarter unaudited results
Ahluwalia Contracts (India) Limited ( ($IN:AHLUCONT) ) has issued an announceme...
08-08 14:53
Pharming Projects FY2026 Total Revenues Of $405M-$425M With 8%-13% Growth Amid Pipeline Investments And Cost Reductions
For 2026, the Company anticipates: Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.Total operating expenses between US$330 million and US$335 million
05-07 14:02
Ducon Infratech Board Clears Capital Expansion and Promoter Loan-to-Equity Plan
The latest update is out from Ducon Infratechnologies Ltd. ( ($IN:DUCON) ). Duc...
04-26 17:12
Pharming granted EU backing for rare immunodeficiency therapy
Pharming Group (PHAR) announced on Friday that an expert panel of the European Medicines Agency, the EU drug regulator, issued a positive opinion recommending marketing authorization for Joenja, a tre...
03-28 00:10
Pharming beats top-line estimates; introduces FY26 outlook
Pharming press release (PHAR): Q4 GAAP EPS of $0.01 in-line. Revenue of $106.5M (+14.9% Y/Y) beats by $0.6M. RUCONEST® revenues amounted to US$86.7 million, a 9% increase compared to the fourth quarte...
03-12 14:33
Pharming Affirms FY2026 Sales Guidance of $405.000M-$425.000M
For 2026, the Company anticipates:Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.Total operating expenses between US$330 million and US$335 million
03-12 14:10
